Gene Therapy for Rare Genetic Diseases


Cite item

Full Text

About the authors

Kenneth Lundstrom

, Pan Therapeutics

Email: info@benthamscience.net

Evangelia Yannaki

Hematology Department, Hematopoietic Cell Transplantation Unit,, Gene and Cell Therapy Center, George Papanikolaou Hospital

Email: info@benthamscience.net

Janice Chou

Section on Cellular Differentiation, Division of Translational Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health

Email: info@benthamscience.net

Fawzy Saad

Department of Gene Therapy, Saad Pharmaceuticals

Author for correspondence.
Email: info@benthamscience.net

References

  1. Lundstrom K. Gene therapy cargos based on viral vector delivery. Current Gene Therapy 2023; 23(2): 111-34.
  2. Kommareddy S, Tiwari SB, Amiji MM. Long-circulating polymeric nanovectors for tumor-selective gene delivery. Technol Cancer Res Treat 2005; 4(6): 615-25.
  3. Tomanin R, Scarpa M. Why do we need new gene therapy viral vectors? Characteristics, limitations and future perspectives of viral vector transduction. Current Gene Therapy 2004; 4(4): 357-72.
  4. Saad FA, Saad JF, Siciliano G, Merlini L, Angelini C. Duchenne muscular dystrophy gene therapy. Current Gene Therapy In press
  5. Chou JY, Mansfield BC. Gene therapy for type I glycogen storage diseases. Current Gene Therapy 2007; 7(2): 79-88.
  6. Psatha N, Georgakopoulou A, Li C, et al. Enhanced HbF reactivation by multiplex mutagenesis of thalassemic CD34+ cells in vitro and in vivo. Blood 2021; 138(17): 1540-53.
  7. Kloess S, Kretschmer A, Stahl L, Fricke S, Koehl U. CAR-expressing natural killer cells for cancer retargeting. Transfus Med Hemother 2019; 46(1): 4-13.
  8. Li Y, Chen J, Tsai SQ, Cheng Y. Easy-Prime: A machine learning-based prime editor design tool. Genome Biol 2021; 22(1): 235.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2024 Bentham Science Publishers